Viewing Study NCT01832857

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 7:00 PM
Ignite Modification Date: 2026-02-13 @ 4:44 AM
Study NCT ID: NCT01832857
Status: TERMINATED
Last Update Posted: 2016-12-29
First Post: 2013-04-12
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Phase 2 Safety, Tolerability and Efficacy Study of CPI-613 in Cancer Patients
Sponsor: Cornerstone Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None metastatic View
None advanced View
None solid tumor View
None cancer View
None colon cancer View
None hepatocellular carcinoma View
None breast cancer View
None lung cancer View
None gastric cancer View
None esophageal cancer View